mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-2010-4-5-311-318mimmun-134Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВЗАИМОСВЯЗЬ РЕГУЛЯТОРНЫХ Т-КЛЕТОК С УРОВНЕМ СА-125 И ОБЪЕМОМ ОПУХОЛЕВОЙ МАССЫ У БОЛЬНЫХ РАКОМ ЯИЧНИКОВRELATION BETWEEN REGULATORY T CELLS, CA-125 LEVEL AND TUMOR MASS IN OVARIAN CANCER PATIENTSЧерныхЕ. Р.ChernykhE. R.ct_lab@mail.ruКургановаЕ. В.KurganovaE. V.ct_lab@mail.ruТихоноваМ. А.TikhonovaM. A.ct_lab@mail.ruЛаскаваяЕ. Г.LaskavayaE. G.ct_lab@mail.ruЛебедеваВ. А.LebedevaV. A.ct_lab@mail.ruОстанинА. А.OstaninA. A.ct_lab@mail.ruНИИ клинической иммунологии СО РАМН, г. НовосибирскРоссияГородская муниципальная клиническая больница № 1, г. НовосибирскРоссия201016072014124-5311318Copyright © Черных Е.Р., Курганова Е.В., Тихонова М.А., Ласкавая Е.Г., Лебедева В.А., Останин А.А., 20142014Черных Е.Р., Курганова Е.В., Тихонова М.А., Ласкавая Е.Г., Лебедева В.А., Останин А.А.Chernykh E.R., Kurganova E.V., Tikhonova M.A., Laskavaya E.G., Lebedeva V.A., Ostanin A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/134Т-клетки регуляторныеFoxP3+СА-125масса опухоли яичниковTregFoxP3+СА-125ovarian tumor massReferencesКурганова Е.В., Тихонова М.А., Коваленко В.Ф., Лебедева В.А., Ласкавая Е.Г., Останин А.А., Черных Е.Р. Характеристика регуляторных Т-клеток у больных раком яичника//Сибирский онкологический журнал. -2008. -№ 6 (30). -С. 40-45.Курганова Е.В., Тихонова М.А., Коваленко В.Ф., Лебедева В.А., Ласкавая Е.Г., Останин А.А., Черных Е.Р. Характеристика регуляторных Т-клеток у больных раком яичника//Сибирский онкологический журнал. -2008. -№ 6 (30). -С. 40-45.Курганова Е.В., Тихонова М.А., Ласкавая Е.Г., Лебедева В.А., Звездина Н.Ю., Безбородова В.И., Гончаров М.А., Лебедева В.А., Останин А.А., Черных Е.Р. Регуляторные Т-клетки при доброкачественных и злокачественных опухолях яичников//Иммунология. -2009. -№ 6. -С. 349-355.Курганова Е.В., Тихонова М.А., Ласкавая Е.Г., Лебедева В.А., Звездина Н.Ю., Безбородова В.И., Гончаров М.А., Лебедева В.А., Останин А.А., Черных Е.Р. Регуляторные Т-клетки при доброкачественных и злокачественных опухолях яичников//Иммунология. -2009. -№ 6. -С. 349-355.Сергеева Н.С., Ермошина Н.В., Мишунина М.П. Использование опухолеассоциированных маркёров для диагностики и контроля за эффективностью терапии у больных с распространенным раком яичников//М.: МНИОИ им. П.А. Герцена, 2002.Сергеева Н.С., Ермошина Н.В., Мишунина М.П. Использование опухолеассоциированных маркёров для диагностики и контроля за эффективностью терапии у больных с распространенным раком яичников//М.: МНИОИ им. П.А. Герцена, 2002.Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., Roncarolo M.G., Levings M.K. Activation-induced FoxP3 in human T effector cells does not suppress proliferation or cytokine production//Intern. Immunol. -2007. -Vol. 19. -P. 345-354.Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., Roncarolo M.G., Levings M.K. Activation-induced FoxP3 in human T effector cells does not suppress proliferation or cytokine production//Intern. Immunol. -2007. -Vol. 19. -P. 345-354.Bast R.S., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma//J. Clin. Invest.-1981. -Vol. 68. -P. 1331-1337.Bast R.S., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma//J. Clin. Invest.-1981. -Vol. 68. -P. 1331-1337.Beyer M., Schultze J.L. Regulatory T cells in cancer//Blood. -2006. -Vol. 108, № 3. -P. 804-811.Beyer M., Schultze J.L. Regulatory T cells in cancer//Blood. -2006. -Vol. 108, № 3. -P. 804-811.Bonelli M., Savitskaya A., Steiner C.-W., Rath E., Smolen J.S., Scheinecker C. Phenotypic and functional analysis of CD4+CD25-Foxp3+ T cells in patients with systemic lupus erythematosus//J. Immunol. -2009. -Vol. 182. -P. 1689-1695.Bonelli M., Savitskaya A., Steiner C.-W., Rath E., Smolen J.S., Scheinecker C. Phenotypic and functional analysis of CD4+CD25-Foxp3+ T cells in patients with systemic lupus erythematosus//J. Immunol. -2009. -Vol. 182. -P. 1689-1695.Canney P.A., Moore M., Wilkinson P.M., James R.D. Ovarian cancer antigen CA-125: a prospective clinical assessment of its role of a tumor marker//Br. J. Cancer. -1984. -Vol. 50, N 6. -P. 765-769.Canney P.A., Moore M., Wilkinson P.M., James R.D. Ovarian cancer antigen CA-125: a prospective clinical assessment of its role of a tumor marker//Br. J. Cancer. -1984. -Vol. 50, N 6. -P. 765-769.Chaput N., Louafi S., Bardier A., Charlotte F., Vaillant J-C., Menegaux F., Rosenzwajg M., Lemoine F., Klatzmann D., Taieb J. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue//Gut. -2009. -Vol. 58, N 4. -P. 520-529.Chaput N., Louafi S., Bardier A., Charlotte F., Vaillant J-C., Menegaux F., Rosenzwajg M., Lemoine F., Klatzmann D., Taieb J. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue//Gut. -2009. -Vol. 58, N 4. -P. 520-529.Chattopadhyay S., Chakraborty N.G., Mukherji B. Regulatory T cells and tumor immunity//Can. Immunol. Immunother. -2005. -Vol. 54. -P. 1153 -1161.Chattopadhyay S., Chakraborty N.G., Mukherji B. Regulatory T cells and tumor immunity//Can. Immunol. Immunother. -2005. -Vol. 54. -P. 1153 -1161.Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., McGrady G., Wahl S.M. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor FoxP3//J. Exp. Med. -2003. -Vol. 198. -P. 1875-1886.Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., McGrady G., Wahl S.M. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor FoxP3//J. Exp. Med. -2003. -Vol. 198. -P. 1875-1886.Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival//Nat. Med. -2004. -Vol. 10, N 9. -P. 942-949.Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival//Nat. Med. -2004. -Vol. 10, N 9. -P. 942-949.Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells//Nat. Immunol. -2003. -Vol. 4. -P. 330-336.Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells//Nat. Immunol. -2003. -Vol. 4. -P. 330-336.Gadducci A., Cosio S., Tana R., Genazzani A.R. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer//Crit. Rev. Oncol. Hematol. -2009. -Vol. 69, N 1. -P. 12-27.Gadducci A., Cosio S., Tana R., Genazzani A.R. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer//Crit. Rev. Oncol. Hematol. -2009. -Vol. 69, N 1. -P. 12-27.Gonzalez H.D., Figueras J. Effect of surgical resection of metastatic disease on immune tolerance to cancer. How a systemic disease could be controlled by a local therapy//Clin. Transl. Oncol. -2007. -Vol. 9. -P. 571-577.Gonzalez H.D., Figueras J. Effect of surgical resection of metastatic disease on immune tolerance to cancer. How a systemic disease could be controlled by a local therapy//Clin. Transl. Oncol. -2007. -Vol. 9. -P. 571-577.Gupta D., Lis C.G. Role of CA-125 in predicting ovarian cancer survival -a review of the epidemiological literature//J. Ovarian. Res. -2009. -Vol. 2: 13 (BioMed Central http://www.ovarianresearch.com/content/2/1/13).Gupta D., Lis C.G. Role of CA-125 in predicting ovarian cancer survival -a review of the epidemiological literature//J. Ovarian. Res. -2009. -Vol. 2: 13 (BioMed Central http://www.ovarianresearch.com/content/2/1/13).Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3//Science. -2003. -Vol. 299. -P. 1057-1061.Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3//Science. -2003. -Vol. 299. -P. 1057-1061.Jonuleit H., Schmitt E. The regulatory T cell family: distinct subsets and their interrelations.//J. Immunol. -2003. -Vol. 171. -P. 6323-6327.Jonuleit H., Schmitt E. The regulatory T cell family: distinct subsets and their interrelations.//J. Immunol. -2003. -Vol. 171. -P. 6323-6327.Kono K., Kawaida H., Takahashi A., Sugai H., Mimura K., Miyagawa N., Omata H., Fujii H. CD4+CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers // Cancer Immunol. Immunother. - 2006. - Vol. 55, N. 9. - P. 1064-1071.Kono K., Kawaida H., Takahashi A., Sugai H., Mimura K., Miyagawa N., Omata H., Fujii H. CD4+CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers // Cancer Immunol. Immunother. - 2006. - Vol. 55, N. 9. - P. 1064-1071.Münstedt K., Krisch M., Sachsse S., Vahrson H. Serum CA-125 levels and survival in advanced ovarian cancer // Arch. Gynecol. Obstet. - 1997. - Vol. 259. - P. 117-123Münstedt K., Krisch M., Sachsse S., Vahrson H. Serum CA-125 levels and survival in advanced ovarian cancer // Arch. Gynecol. Obstet. - 1997. - Vol. 259. - P. 117-123Shafer-Weaver K.A, Anderson M.J., Stagliano R., Malyguine A., Greenberg N.M., Hurwitz A.A Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells//J. Immunol. -2009. -Vol. 183, N 8. -P. 4848-4852.Shafer-Weaver K.A, Anderson M.J., Stagliano R., Malyguine A., Greenberg N.M., Hurwitz A.A Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells//J. Immunol. -2009. -Vol. 183, N 8. -P. 4848-4852.Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells a common basis between tumor immunity and autoimmunity//J. Immunol. -1999. -Vol. 163. -P. 5211-5218.Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells a common basis between tumor immunity and autoimmunity//J. Immunol. -1999. -Vol. 163. -P. 5211-5218.Tokuno K., Hazama S., Yoshino S., Yoshida S., Oka M. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer//Anticancer Res. -2009. -Vol. 29, N 5. -P. 1527-1532.Tokuno K., Hazama S., Yoshino S., Yoshida S., Oka M. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer//Anticancer Res. -2009. -Vol. 29, N 5. -P. 1527-1532.Walker M. R., Carson B.D., Nepom G.T., Ziegler S.F., Buckner J.H. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25-cells//Proc. Natl. Acad. Sci. USA. -2005. -Vol. 102. -P. 4103-4108.Walker M. R., Carson B.D., Nepom G.T., Ziegler S.F., Buckner J.H. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25-cells//Proc. Natl. Acad. Sci. USA. -2005. -Vol. 102. -P. 4103-4108.Wei S., Kryczek I., Zou W. Regulatory T-cells compartmentalization and trafficking//Blood. -2006. -Vol. 108. -P. 426-431.Wei S., Kryczek I., Zou W. Regulatory T-cells compartmentalization and trafficking//Blood. -2006. -Vol. 108. -P. 426-431.Zhou G., Levitsky H.I. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance//J. Immunol. -2007.-Vol. 178. -P. 2155-2162.Zhou G., Levitsky H.I. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance//J. Immunol. -2007.-Vol. 178. -P. 2155-2162.Zou W. Regulatory T cells, tumor immunity and immunotherapy//Nat. Rev. Immunol. -2006. -Vol. 6. -P. 295-307.Zou W. Regulatory T cells, tumor immunity and immunotherapy//Nat. Rev. Immunol. -2006. -Vol. 6. -P. 295-307.
The authors declare that there are no conflicts of interest present.